Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. It provides teleradiology services and develops artificial intelligence applications for real-world medical imaging. The company's solutions include the Nanox Multi Source System, Nanox.CLOUD, Nanox.MARKETPLACE, Nanox.CONNECT, AI-based software imaging solutions, and teleradiology services. It also offers the Real+ Osteoporosis Care Management Platform, AI-based aortic valve calcification measurement, AI-based body composition measurement, and Nanox Health IT. Founded in 2011, the company is headquartered in Petah Tikva, Israel.
Nanox Q1: Going-Concern Doubt, Guidance Withdrawn, Lawsuits Mount
▼
Q1 2026: Going-concern doubt and guidance withdrawn Nanox reported Q1 revenue of $4.3 million but withdrew its 2026 revenue target and said it will no longer give annual guidance. It also disclosed $44.2 million in cash is not enough to fund the next 12 months, raising substantial doubt about its ability to continue as a going concern. This directly pressures the stock because it signals possible cash shortage and no clear revenue visibility.
This is the core new fundamental event that explains the period's negative move.
▼
Securities class action lawsuits over alleged misleading statements Multiple law firms announced securities class actions alleging Nanox overstated efficiency gains and demand while hiding manufacturing problems. The lawsuits cover purchases from March 31, 2025 to April 17, 2026, with a lead plaintiff deadline of August 11, 2026. This adds legal costs and uncertainty, weighing on the stock.
New legal actions create fresh financial and reputational risk for NNOX.
▼
South Korea operations may be sold or wound down Nanox is evaluating strategic alternatives for its South Korea operations, including a potential sale or wind-down. This follows a $17.5 million impairment and $18 million restructuring plan disclosed in April. A sale or shutdown could reduce future costs but also signals that part of the business is failing, hurting investor confidence.
This is a new strategic update that affects the company's cost structure and future prospects.
▲
First commercial Nanox.ARC system in use at RadNet Nanox reported that a Nanox.ARC system is now in commercial use at a RadNet facility. This is a small but important milestone showing the product is finally being deployed in a real clinical setting. If it leads to more orders, it could support future revenue, but so far it is just one unit.
This is the only new positive operational development that could offset the negative financial news.
Latest
▼3
Nano-X: Q2 revenue up 37% but going-concern doubt and lawsuits weigh
▼
Securities class action lawsuits pile up Multiple law firms filed class actions alleging Nano-X overstated efficiency and demand, hid rising costs and cash burn, and misled investors. Legal costs, potential damages, and reputational damage weigh on the stock, though the suits are still pending.
This is a major new legal overhang that directly pressures NNOX shares.
▼
Going-concern doubt after Q2 report Nano-X ended Q2 with $31.4 million cash, down from $60 million, and management warned of substantial doubt about continuing as a going concern. A $40.7 million impairment and $55.5 million net loss deepen fears of a cash crunch, pushing the stock down.
Going-concern doubt is a severe new risk that directly threatens the company's survival and stock price.
◆
Revenue growth but slow commercialization Q2 revenue rose 37% to $4.2 million, with teleradiology up 14% and AI/software adding $1 million. The first Nanox Imaging Network site began collecting insurance payments, but management admitted commercialization is slower than expected, tempering the positive growth.
This shows the underlying business is growing but not fast enough to offset cash burn, a key tension for the stock.
▼
Restructuring and manufacturing shift Nano-X is idling its South Korean chip fabrication, cutting that workforce by 67% and Israeli headcount by 15%, and shifting to third-party manufacturing. The plan saves only $2 million a year from 2027, raising doubts about its impact.
The restructuring is a direct response to the cash crisis and signals deeper operational problems.
Q3 2026
▼3
Nano-X: Q2 revenue up 37% but going-concern doubt and lawsuits weigh
▼
Securities class action lawsuits pile up Multiple law firms filed class actions alleging Nano-X overstated efficiency and demand, hid rising costs and cash burn, and misled investors. Legal costs, potential damages, and reputational damage weigh on the stock, though the suits are still pending.
This is a major new legal overhang that directly pressures NNOX shares.
▼
Going-concern doubt after Q2 report Nano-X ended Q2 with $31.4 million cash, down from $60 million, and management warned of substantial doubt about continuing as a going concern. A $40.7 million impairment and $55.5 million net loss deepen fears of a cash crunch, pushing the stock down.
Going-concern doubt is a severe new risk that directly threatens the company's survival and stock price.
◆
Revenue growth but slow commercialization Q2 revenue rose 37% to $4.2 million, with teleradiology up 14% and AI/software adding $1 million. The first Nanox Imaging Network site began collecting insurance payments, but management admitted commercialization is slower than expected, tempering the positive growth.
This shows the underlying business is growing but not fast enough to offset cash burn, a key tension for the stock.
▼
Restructuring and manufacturing shift Nano-X is idling its South Korean chip fabrication, cutting that workforce by 67% and Israeli headcount by 15%, and shifting to third-party manufacturing. The plan saves only $2 million a year from 2027, raising doubts about its impact.
The restructuring is a direct response to the cash crisis and signals deeper operational problems.
News & notes movingNNOX
United KingdomUnited States
NNOX▲
Nanox.AI Signs Exclusive Three-Year UK Reseller Deal With Vertec Scientific
Nano-X Imaging Ltd. is advancing its Nanox.AI medical imaging analytics subsidiary on two fronts this month, led by an exclusive three-year UK reseller agreement with Vertec Scientific for its HealthOST bone solution that includes minimum annual license commitments. The deal targets a UK market where approximately 86,000 vertebral fragility fractures occur annually, with most remaining undiagnosed. Separately, an optimization project with Intel demonstrates a path for Nanox.AI's imaging AI framework to run inference locally on hospital hardware rather than relying entirely on the cloud. The company said routine CT imaging can capture information related to the spine, coronary arteries, liver and other areas beyond the original clinical indication, creating an opportunity to support clinical evaluation of findings that might otherwise go unnoticed.
NNOX · Demand · Positive Exclusive three-year UK reseller deal with Vertec Scientific for HealthOST includes minimum annual license commitments, a concrete product order.
NNOX · Technology · Positive Intel optimization project shows Nanox.AI's imaging AI framework can run inference locally on hospital hardware instead of relying on the cloud.
Vertec Scientific · Demand · Positive Vertec Scientific signs exclusive three-year UK reseller agreement to sell Nanox.AI's HealthOST bone solution.
Nano-X Imaging reported second-quarter revenue of $4.2 million, up 37% year over year, while booking a $40.7 million impairment charge and warning that its remaining cash raises substantial doubt about its ability to continue as a going concern. The company held $31.4 million as of June 30, down from $60 million as of December 31, 2025, and CFO Guy Nathanzon said the resources raise substantial doubt about the going-concern outlook. The impairment charge, triggered by a falling share price and lower revenue forecasts for the AI unit, dragged GAAP gross margin to negative 1,051% from negative 107% a year earlier and pushed the GAAP net loss to $55.5 million. Teleradiology grew 14% year over year to $3 million, the AI and software line added $1 million, and the first Nanox Imaging Network site, in Philadelphia, has begun collecting insurance payments of $200 to $700 per claim, with management projecting a fully utilized site could generate $500,000 to $1 million a year. CEO Erez Meltzer said commercialization has taken longer than expected, and the company's response is a restructuring that idles chip fabrication in South Korea, cuts that workforce by 67%, trims Israeli headcount by 15%, and shifts manufacturing to third-party partners, a plan expected to save just $2 million a year starting in 2027.
NNOX · Capital · Negative Q2 revenue grew 37% but a $40.7M impairment, negative 1,051% gross margin, $55.5M net loss and going-concern doubt over dwindling cash dominate the report.
NNOX · Demand · Neutral Teleradiology grew 14% to $3M, AI/software added $1M, and the first Nanox Imaging Network site began collecting $200-$700 insurance claims, though management admits commercialization is slower than expected.
Nanox.AI Optimizes Medical Imaging AI for Intel Core Ultra Processors
Nanox.AI, a subsidiary of Nano-X Imaging, has optimized its medical imaging AI application framework for Intel Core Ultra processors using Intel's OpenVINO toolkit. The framework is designed to run AI applications on on-premise edge devices within healthcare facilities, enabling organizations to evaluate and deploy CT imaging AI while keeping data within their own infrastructure. The optimized framework ran inference successfully on Intel Core Ultra-class hardware, demonstrating suitability for local AI processing in medical imaging. Intel Core Ultra processors provide a heterogeneous AI architecture with CPU, GPU, and NPU resources, and OpenVINO helps optimize AI workloads across Intel hardware, supporting local inference at the edge and reducing dependence on cloud connectivity. Nanox.AI's solutions analyze routine CT scans to identify findings correlated with chronic conditions in cardiac, liver, and bone health, aiming to derive additional clinical value from existing scans.
Artificial Intelligence › Edge & On-device AI Silicon ▲Technology
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Technology
NNOX · Technology · Positive Nanox.AI, a subsidiary, optimized its medical imaging AI framework for Intel Core Ultra, demonstrating successful local inference and expanding its edge deployment capabilities.
INTC · Technology · Positive Intel's Core Ultra processors and OpenVINO toolkit are highlighted as enabling optimized AI inference for medical imaging, showcasing their technology's capability.
Nano-X Imaging investors face August 11 deadline to seek lead plaintiff in securities fraud lawsuit
Glancy Prongay Wolke & Rotter LLP reminds investors that August 11, 2026 is the deadline to file a lead plaintiff motion in a class action lawsuit against Nano-X Imaging Ltd. The suit covers purchasers of Nano-X securities between March 31, 2025 and April 17, 2026. On April 20, 2026, Nano-X reported a fourth-quarter 2025 net loss of $33.4 million, including a $17.5 million impairment charge tied to restructuring at its Korean chip manufacturing facility, and announced its CFO would step down, causing the stock to drop 24.4% to $2.16 per share. The complaint alleges the company made materially false and misleading statements and failed to disclose that its production and manufacturing operations were poorly aligned with demand, leading to increased expenses and cash burn that ultimately forced disruptive remedial measures.
Law Offices of Howard G. Smith Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions Against HUBG, PLNT, INTU, NNOX
The Law Offices of Howard G. Smith reminds investors that securities fraud class action lawsuits have been filed against Hub Group, Planet Fitness, Intuit, and Nano-X Imaging, with lead plaintiff deadlines approaching. For Hub Group, the class period is April 28, 2023 to May 11, 2026, with a deadline of August 28, 2026; the complaint alleges material misstatements in financial statements from Q1 2023 to Q4 2024 and Q1 2025 to Q3 2025. Planet Fitness faces a class period of November 6, 2025 to May 6, 2026 and a deadline of September 14, 2026, over claims it misled investors about membership growth and a Black Card price increase. Intuit's class period runs from August 22, 2025 to May 20, 2026, with a September 8, 2026 deadline, alleging overstated competitive advantages and unrealistic TurboTax revenue guidance. Nano-X Imaging has a class period of March 31, 2025 to April 17, 2026 and the earliest deadline of August 11, 2026, accused of overstating efficiency gains and demand while facing rising operating expenses.
SueWallSt alerts Nano-X Imaging investors of securities class action deadline
SueWallSt has alerted investors in Nano-X Imaging Ltd. of a pending securities class action, with a lead plaintiff deadline of August 11, 2026. The lawsuit covers purchases between March 31, 2025 and April 17, 2026, and alleges the company concealed escalating operating expenses and cash consumption at its South Korean chip fabrication facility. Nano-X shares fell 24.39% to $2.155 on April 20, 2026, after the company disclosed a $33.4 million quarterly net loss, a $17.5 million impairment charge, and a complete restructuring of its Korean manufacturing operations. The complaint claims management publicly characterized spending as disciplined while internal costs were allegedly far exceeding demand, and that a $15 million registered direct offering in November 2025 was conducted as the cash position deteriorated. Investors who purchased shares during the class period and suffered losses may be eligible to recover damages, with no upfront costs required.
NNOX · Capital · Negative Securities class action lawsuit alleging concealed costs and losses, plus disclosed $33.4M net loss and $17.5M impairment charge.
Nano-X Imaging investors face August 11 deadline in securities fraud lawsuit
The Schall Law Firm reminds investors of a class action lawsuit against Nano-X Imaging Ltd. for alleged securities fraud. The suit covers investors who purchased Nano-X securities between March 31, 2025 and April 17, 2026, with a lead plaintiff deadline of August 11, 2026. The complaint alleges the company made false and misleading statements by overstating demand for its products and operational efficiency gains, while in reality it was poorly aligned with customer demands and suffered increased cash burn. Investors who suffered losses are encouraged to contact the firm before the deadline.
Law Offices of Howard G. Smith Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions Against Erasca, Nano-X, Microsoft, and Black Rock Coffee Bar
The Law Offices of Howard G. Smith reminds investors that securities fraud class action lawsuits have been filed against Erasca, Nano-X Imaging, Microsoft, and Black Rock Coffee Bar, with lead plaintiff deadlines approaching in August 2026. For Erasca, the class period runs from January 14, 2025 to April 26, 2026, with a deadline of August 10, 2026, and the complaint alleges that preclinical data for ERAS-0015 was based on improper comparisons and risked patent and trade secret violations. Nano-X Imaging faces a class period from March 31, 2025 to April 17, 2026, with a deadline of August 11, 2026, and allegations that the company overstated efficiency gains and demand while its production was poorly aligned with demand, leading to increased expenses and restructuring charges. Microsoft's class period is May 1, 2025 to January 28, 2026, with a deadline of August 11, 2026, and the complaint claims that Copilot products suffered from brand positioning and interoperability problems, the company's AI model ranked below competitors, and it failed to convert a significant percentage of commercial Microsoft 365 users to paid Copilot subscriptions. Black Rock Coffee Bar's class period runs from September 12, 2025 to May 12, 2026, with a deadline of August 17, 2026, and the complaint alleges that new store openings cannibalized existing revenue and the company overstated how its expansion strategy avoided sales transfer. Investors who suffered losses can contact the Law Offices of Howard G. Smith to discuss their legal rights.
BRCB · Regulation · Negative Securities fraud class action alleges new store openings cannibalized existing revenue and overstated expansion strategy.
ERAS · Regulation · Negative Securities fraud class action alleges preclinical data for ERAS-0015 was based on improper comparisons and risked patent/trade secret violations.
MSFT · Regulation · Negative Securities fraud class action alleges Copilot products had brand positioning and interoperability problems, AI model ranked below competitors, and low conversion to paid subscriptions.
NNOX · Regulation · Negative Securities fraud class action alleges overstated efficiency gains and demand, and poor production alignment leading to increased expenses and restructuring charges.
Portnoy Law Firm files class action against Nano-X Imaging over alleged misleading statements
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors who purchased Nano-X Imaging Ltd. securities between March 31, 2025 and April 17, 2026. The complaint alleges that the company overstated efficiency gains and product demand, misaligned production with demand, and experienced rising operating expenses and cash burn, which increased the likelihood of disruptive remedial measures and restructuring charges. On April 20, 2026, Nano-X reported a fourth-quarter net loss of $33.4 million, including a $17.5 million impairment charge tied to a restructuring at its Korean chip manufacturing facility, and disclosed a shift to an outsourced production model along with the planned departure of its CFO. Investors have until August 11, 2026 to seek lead plaintiff status.
Holzer & Holzer Announces Lead Plaintiff Deadlines for Class Actions Against Erasca, Nano-X Imaging, and Peabody Energy
Holzer & Holzer LLC has announced upcoming deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against Erasca Inc., Nano-X Imaging Ltd., and Peabody Energy Corporation. The Erasca suit, covering purchases between January 14, 2025 and April 26, 2026, alleges misleading statements about ERAS-0015, with a lead plaintiff deadline of August 10, 2026. The Nano-X Imaging suit, for purchases between March 31, 2025 and April 17, 2026, concerns claims about operational efficiency and cash burn, with a deadline of August 11, 2026. The Peabody Energy suit, for purchases between October 14, 2024 and May 4, 2026, involves allegations regarding the Centurion mine ramp-up and growth outlook, with a deadline of August 24, 2026. Investors who suffered losses are encouraged to contact the firm to discuss their legal rights.
Bronstein, Gewirtz & Grossman LLC Files Class Action Against Nano-X Imaging
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Nano-X Imaging Ltd. and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired Nano-X securities between March 31, 2025 and April 17, 2026. The complaint claims defendants made false and misleading statements about efficiency gains and product demand, while the company actually faced poorly aligned production, rising operating expenses, and increased cash burn, ultimately leading to a higher likelihood of disruptive remedial measures and significant restructuring charges. Investors have until August 11, 2026 to seek lead plaintiff appointment. The law firm is handling the case on a contingency fee basis.
NNOX · Regulation · Negative Class action lawsuit alleging securities law violations, which typically leads to legal costs, reputational damage, and potential financial penalties.
Nano-X Imaging investors face August 11 lead plaintiff deadline in securities fraud lawsuit
Glancy Prongay Wolke & Rotter LLP reminds investors of the August 11, 2026 deadline to file a lead plaintiff motion in a class action lawsuit against Nano-X Imaging Ltd. The suit covers those who purchased or acquired Nano-X securities between March 31, 2025 and April 17, 2026. On April 20, 2026, Nano-X reported a fourth-quarter net loss of $33.4 million, including a $17.5 million impairment charge tied to restructuring at its Korean chip facility, and announced its CFO would step down, causing shares to drop 24.4% to $2.16. The complaint alleges the company made false or misleading statements about operational efficiency and product demand, concealing misaligned production, rising expenses, and the likelihood of disruptive remedial measures.
Levi & Korsinsky Alerts Nano-X Imaging Stockholders of Securities Class Action
Levi & Korsinsky alerts Nano-X Imaging stockholders of a pending securities class action. The class period runs from March 31, 2025 through April 17, 2026, and the court has set August 11, 2026 as the deadline to apply for lead plaintiff appointment. The lawsuit alleges that Nano-X concealed escalating operating expenses and cash consumption at its South Korean chip fabrication facility, while publicly characterizing spending as disciplined and efficient. Nano-X shares fell 24.39% on April 20, 2026 after the company disclosed a 33.4 million dollar quarterly net loss, a 17.5 million dollar impairment charge, and the need for a complete restructuring of its Korean manufacturing operations. Investors who purchased NNOX stock during the class period and suffered losses may be eligible to participate.
NNOX · Capital · Negative Lawsuit alleges concealed operating expenses and cash consumption; shares fell 24.39% after disclosure of net loss, impairment, and restructuring.
Faruqi & Faruqi Reminds Nano-X Imaging Investors of August 11, 2026 Securities Class Action Deadline
Faruqi & Faruqi, LLP reminds investors of the August 11, 2026 deadline to seek lead plaintiff status in a securities class action against Nano-X Imaging Ltd. The lawsuit alleges the company and its executives made false or misleading statements about operational efficiency, product demand, and manufacturing performance, concealing rising expenses and cash burn that led to a restructuring. On April 20, 2026, Nano-X reported a fourth-quarter net loss of $33.4 million, including a $17.5 million impairment charge tied to its Korean chip manufacturing facility, and announced the CFO's upcoming departure. The stock fell 24.39% to $2.1550 per share that day. Investors who purchased Nano-X securities between March 31, 2025 and April 17, 2026 may be eligible to participate.
רוזן עורכי דין מזכירים למשקיעי Nano-X Imaging מועד אחרון לתביעה ייצוגית
משרד רוזן עורכי דין מזכיר למשקיעי Nano-X Imaging Ltd שרכשו ניירות ערך בין 31 במרץ 2025 ל-17 באפריל 2026 כי המועד האחרון להגשת תביעה ייצוגית בניירות ערך הוא 11 באוגוסט 2026. על פי התביעה, הנתבעים מסרו הצהרות כוזבות ומטעות בנוגע לשיפורי היעילות והביקוש למוצרי Nano-X, בעוד שבפועל פעילות הייצור לא תאמה את הביקוש, מה שהוביל לעלייה בהוצאות התפעול ובצריכת המזומנים. כתוצאה מכך, נטען כי החברה נאלצה לנקוט צעדי תיקון שגררו הוצאות ארגון מחדש וירידת ערך, וכאשר הפרטים האמיתיים נחשפו, המשקיעים ספגו נזקים. משרד רוזן, המתמחה בתביעות ייצוגיות בניירות ערך, מדגיש את ניסיונו בהשגת הסדרים משמעותיים, כולל ההסדר הגדול ביותר אי פעם נגד חברה סינית, והחזרת מאות מיליוני דולרים למשקיעים. משקיעים המעוניינים להצטרף לתביעה או לשמש כתובע מרכזי יכולים לפנות למשרד עד למועד האחרון.
Rosen Law Firm Reminds Nano-X Imaging Investors of August 11 Lead Plaintiff Deadline
Rosen Law Firm reminds purchasers of Nano-X Imaging Ltd. securities between March 31, 2025 and April 17, 2026 of the August 11, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that throughout the class period, defendants made false and misleading statements and failed to disclose that they overstated efficiency gains and demand, while Nano-X's production was poorly aligned with demand, leading to increased operating expenses and cash burn, and a heightened likelihood of disruptive remedial measures with significant restructuring and impairment charges. Investors may be entitled to compensation through a contingency fee arrangement without out-of-pocket costs. To join or seek lead plaintiff status, investors must contact the firm before the deadline.
Bragar Eagel & Squire Announces Class Action Lawsuit Against Nano-X Imaging
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Nano-X Imaging Ltd. in the United States District Court for the District of New Jersey on behalf of investors who purchased or acquired Nano-X securities between March 31, 2025 and April 17, 2026. The lawsuit alleges that throughout the class period, defendants made false or misleading statements and failed to disclose that Nano-X overstated efficiency gains and demand, its production was poorly aligned with demand, it faced significantly increased operating expenses and cash burn, and it was likely to take disruptive remedial measures with restructuring and impairment charges. On April 20, 2026, Nano-X reported a fourth quarter 2025 net loss of $33.4 million, including a $17.5 million impairment charge from restructuring its Korean chip manufacturing facility, and announced the CFO's departure, causing shares to drop 25% from $2.85 to $2.15. Investors have until August 11, 2026 to seek lead plaintiff appointment.
Bronstein, Gewirtz & Grossman LLC Files Class Action Against Nano-X Imaging
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Nano-X Imaging Ltd. and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired Nano-X securities between March 31, 2025 and April 17, 2026. The complaint claims the company made false and misleading statements about efficiency gains and product demand, while in reality its production was poorly aligned with demand, leading to increased operating expenses and cash burn. Investors have until August 11, 2026 to seek lead plaintiff appointment. The law firm represents investors on a contingency fee basis.
Law Offices of Howard G. Smith Reminds Investors of Lead Plaintiff Deadlines in Securities Class Actions Against Erasca, Nano-X, Microsoft, and Black Rock Coffee Bar
The Law Offices of Howard G. Smith reminds investors that securities fraud class action lawsuits have been filed against Erasca, Nano-X Imaging, Microsoft, and Black Rock Coffee Bar, with lead plaintiff deadlines ranging from August 10 to August 17, 2026. The Erasca complaint alleges that defendants misled investors about ERAS-0015's preclinical data and related patent risks. The Nano-X case claims the company overstated efficiency gains and demand while facing rising expenses and cash burn. Microsoft is accused of concealing problems with its Copilot products, including poor AI model performance and low paid subscription conversion. Black Rock Coffee Bar allegedly failed to disclose that new store openings were cannibalizing existing sales. Investors who suffered losses may contact the law firm to discuss their legal rights.
BRCB · Demand · Negative Allegedly failed to disclose that new store openings were cannibalizing existing sales, indicating weaker demand.
ERAS · Technology · Negative Allegedly misled investors about ERAS-0015's preclinical data and related patent risks, questioning technology viability.
MSFT · Technology · Negative Accused of concealing problems with Copilot products, including poor AI model performance and low paid subscription conversion.
NNOX · Demand · Negative Allegedly overstated efficiency gains and demand while facing rising expenses and cash burn.
Frank R. Cruz Law Offices Reminds Investors of Class Action Deadlines for BTGO, ERAS, NNOX, and MSFT
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of BitGo Holdings, Erasca, Nano-X Imaging, and Microsoft, with lead plaintiff deadlines in August 2026. For BitGo, the class period runs from January 22, 2026 to May 13, 2026, with a deadline of August 7, 2026; the complaint alleges the company understated risks from declining digital asset prices. Erasca's class period is January 14, 2025 to April 26, 2026, with a deadline of August 10, 2026, and the suit claims preclinical data for ERAS-0015 was based on improper comparisons and risked patent violations. Nano-X Imaging faces a class period from March 31, 2025 to April 17, 2026, with a deadline of August 11, 2026, over allegations it overstated efficiency gains and demand while masking rising expenses and cash burn. Microsoft's class period is May 1, 2025 to January 28, 2026, also with an August 11, 2026 deadline, and the complaint alleges the company failed to disclose significant problems with its Copilot products, poor AI model benchmarks, and the need for billions in extra capital expenditures that diverted resources from Azure, leading to low paid subscription conversion and market share losses.
BTGO · Regulation · Negative Class action alleges BitGo understated risks from declining digital asset prices.
ERAS · Regulation · Negative Class action lawsuit alleges preclinical data for ERAS-0015 was based on improper comparisons and risked patent violations.
MSFT · Technology · Negative Class action alleges Microsoft failed to disclose significant problems with Copilot products, poor AI model benchmarks, and low paid subscription conversion.
NNOX · Demand · Negative Class action alleges Nano-X overstated efficiency gains and demand while masking rising expenses and cash burn.
Holzer & Holzer Announces Lead Plaintiff Deadlines for Class Actions Against Nano-X Imaging, Peabody Energy, and First Solar
Holzer & Holzer reminds investors of upcoming lead plaintiff deadlines in shareholder class action lawsuits against Nano-X Imaging, Peabody Energy, and First Solar. The Nano-X Imaging case covers purchases between March 31, 2025 and April 17, 2026, with a lead plaintiff deadline of August 11, 2026. The Peabody Energy case covers purchases between October 14, 2024 and May 4, 2026, with a lead plaintiff deadline of August 24, 2026. The First Solar case covers purchases between February 26, 2025 and February 24, 2026, also with a lead plaintiff deadline of August 24, 2026. Investors who suffered losses are encouraged to contact the firm to discuss their legal rights.
Rosen Law Firm Reminds Nano-X Imaging Investors of August 11 Lead Plaintiff Deadline
Rosen Law Firm reminds purchasers of Nano-X Imaging Ltd. securities between March 31, 2025 and April 17, 2026 of the August 11, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that throughout the class period, defendants made false and misleading statements and failed to disclose that they overstated efficiency gains and demand, while Nano-X’s production was poorly aligned with demand, leading to increased operating expenses and cash burn, and a heightened likelihood of disruptive remedial measures with significant restructuring and impairment charges. Investors who purchased Nano-X securities during the class period may be entitled to compensation through a contingency fee arrangement without out-of-pocket costs. To join the class action or seek lead plaintiff status, investors must move the Court by the August 11 deadline.
ON Semiconductor to acquire Synaptics in $7B all-stock deal
ON Semiconductor agreed to acquire Synaptics in an all-stock deal valued at $7 billion, sending ON shares down 13% while Synaptics rose 6%. Under the fixed exchange ratio, Synaptics shareholders will receive 1.35 ON shares for each Synaptics share, and the combined company targets a total addressable market of $243 billion by 2030. The transaction is expected to be accretive to adjusted earnings within 18 months of closing and generate $200 million in annual synergies. Separately, Titan Mining surged 42% after the U.S. Army awarded it long-term leases to build a graphite purification facility at two military bases, part of a broader Pentagon push for domestic critical-minerals processing. Wise Group gained 7% on plans for a share buyback exceeding $500 million and reiterated medium-term targets of 15%–20% net revenue CAGR and a 15%–20% income before tax margin. Nano-X Imaging dropped 12% after reporting first-quarter revenue of $4.3 million, missing estimates, and withdrawing its 2026 outlook due to going-concern uncertainty.
Nano-X Imaging reported first-quarter revenue of $4.31 billion, a year-over-year increase of over 152,000 percent, beating estimates by the same amount. GAAP loss per share was 20 cents, matching expectations. Shares fell 3 percent in pre-market trading.
Nanox Reports Q1 2026 Revenue of $4.3 Million and Withdraws Annual Guidance
Nanox announced first quarter 2026 revenue of $4.3 million, up from $2.8 million a year earlier, but withdrew its 2026 revenue target and said it will no longer provide annual guidance due to unpredictable deployment timelines. The company's GAAP net loss widened to $14.3 million from $13.2 million, while non-GAAP net loss attributable to ordinary shares was $11.1 million. Nanox also disclosed that its cash position of $44.2 million as of March 31 is insufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern. The company is evaluating strategic alternatives for its South Korea operations, including a potential sale or wind-down, and reported that a Nanox.ARC system is now in commercial use at a RadNet facility.
BlackBerry, McCormick, Darden Restaurants among major earnings before Thursday's open
Several major companies are scheduled to report earnings before the market opens on Thursday. Among them are BlackBerry Limited, McCormick & Company, Darden Restaurants, Nano-X Imaging, and Winnebago Industries. Other companies slated to release results include Acuity Brands, Commercial Metals, TD SYNNEX, and Yiren Digital.
Bragar Eagel & Squire Files Class Action Against Nano-X Imaging Over Alleged Misstatements
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Nano-X Imaging Ltd. in the United States District Court for the District of New Jersey on behalf of investors who purchased Nano-X securities between March 31, 2025 and April 17, 2026. The lawsuit alleges that the company made false and misleading statements about efficiency gains and product demand, while in reality its manufacturing operations were poorly aligned with demand, leading to increased operating expenses and cash burn. On April 20, 2026, Nano-X reported a fourth-quarter net loss of $33.4 million, including a $17.5 million impairment charge from a restructuring at its Korean chip facility, and announced the CFO's departure; shares fell 25% from $2.85 to $2.15. Investors have until August 11, 2026 to seek lead plaintiff appointment.
Frank R. Cruz Law Firm Reminds Investors of Class Action Deadlines for BTGO, ERAS, NNOX, and MSFT
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of BitGo Holdings, Erasca, Nano-X Imaging, and Microsoft, with lead plaintiff deadlines approaching in August 2026. The suit against BitGo alleges the company understated risks from declining digital asset prices, with a deadline of August 7. Erasca faces claims it misrepresented preclinical data for ERAS-0015 and risked patent violations, with a deadline of August 10. Nano-X is accused of overstating efficiency gains and demand while concealing rising costs and cash burn, with a deadline of August 11. Microsoft allegedly failed to disclose problems with its Copilot products, weak AI model benchmarks, and billions in needed capital expenditures, also with an August 11 deadline.
USA
